




RealRate

PHARMACEUTICAL 2022

Evoke Pharma Inc
Rank 380 of 466



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Evoke Pharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evoke Pharma Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 34% points. The greatest weakness of Evoke Pharma Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 111% points.

The company's Economic Capital Ratio, given in the ranking table, is -28%, being 105% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	10,561
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,406
Liabilities, Non-Current	5,612
Other Assets	12
Other Compr. Net Income	0
Other Expenses	328
Other Liabilities	0
Other Net Income	-386
Other Revenues	1,618
Property and Equipment	0
Research and Development	590
Selling, General and Administrative Expense	8,851

Output Variable	Value in 1000 USD
Assets	10,573
Liabilities	7,018
Expenses	9,770
Revenues	1,618
Stockholders Equity	3,555
Net Income	-8,538
Comprehensive Net Income	-8,538
Economic Capital Ratio	-28%